(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) rose by a staggering 11.17% to $0.45 at 11:24 EST on Wednesday, following the last session’s downward trend. NASDAQ is jumping 0.18% to $12,102.21, after two sequential sessions in a row of losses. This seems, at the moment, a somewhat up trend trading session today.
Xenetic Biosciences’s last close was $0.40, 64.34% below its 52-week high of $1.13.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-0.47.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.9%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 46.4%, now sitting on 1.71M for the twelve trailing months.
Volatility
Xenetic Biosciences’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.30%, a positive 0.04%, and a positive 4.67%.
Xenetic Biosciences’s highest amplitude of average volatility was 3.89% (last week), 3.84% (last month), and 4.67% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 8.3% and 42.1%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Xenetic Biosciences’s EBITDA is 6.09.
More news about Xenetic Biosciences (XBIO).
